

SPECIAL ADVISORY • MAY 2018

TEST CHANGE: URINE CHAIN OF CUSTODY

The Toxicology Department has introduced a new array of test panels for partners who use chain-of-custody urine drugtesting services (HNL-53 requisition form) effective immediately. Changes have also been made to our report to deliver a more specific, better organized display of results.

NEW TESTS WITH EXPANDED DRUG DETECTION CAPABILITIES

HNL is using the latest in immunoassay technology to improve detection of 6MAM (heroin metabolite) and MDMA (Ecstasy). All 12 panels in the chart (see below) are available for your convenience. To order the new tests:



1. Write the corresponding test code in the custom area of the HNL-53 requisition form.
2. Beginning January 2, 2019, the current test panels will be discontinued and HNL will no longer offer screening for Propoxyphene.

In the coming weeks, new HNL-53 requisition forms will be issued to reflect the changes in chain-of-custody tests for urine. Your sales representative will contact you soon regarding the new forms.

CURRENT HNL CHAIN OF CUSTODY TESTS							NEW HNL CHAIN OF CUSTODY TESTS					
							NEW!					
Urine	IM5	IM5L	IM7	IM9L	IMDS	IM10	FDU1	FDU2	FDU3	FDU4	FDU5	FDU6
Amphetamines	X	X	X	X	X	X	X	X	X	X	X	X
THC	X	X	X	X	X	X	X	X	X	X	X	X
Cocaine	X	X	X	X	X	X	X	X	X	X	X	X
Opiate 2000	X		X		X		X		X		X	
Opiate 300		X		X		X		X		X		X
PCP	X	X	X	X	X	X	X	X	X	X	X	X
Barbiturates			X	X	X	X			X	X	X	X
Benzodiazepines			X	X	X	X			X	X	X	X
Methadone				X	X	X				X	X	X
Propoxyphene				X	X	X						
Oxycodone						X						X
MDMA							X	X	X	X	X	X
6MAM							X	X	X	X	X	X
Biochemical Checks	X	X	X	X	X	X	X	X	X	X	X	X

ENHANCED REPORT WITH MORE SPECIFIC DATA, ELECTRONIC TRACKING

The new tests also come with an enhanced report that features the addition of quantitative results for positive assays. The report has been modified to include an organized display of cutoff concentrations and confirmations, and our certifying scientists now use electronic signature technology.

 Health Network LABORATORIES* 794 Roble Road Allentown, PA 18109-9110		Urine Chain of Custody Report Jeffrey D. Wisotzkey PhD, HCLD Laboratory Director Daniel F. Brown MD, MBA Medical Director Phone: (484) 425-8170 Toll Free: (877) 402-4221 www.healthnetworklabs.com				
Name: HNL, DEMO COC		Sex: M	Date of Birth: 10/13/1953	Age: 64Y	Social Security # N/A	Client ID: S123
Address: 123 TEST DR SUITE 456 HOLLA, PA 18061		Phone: 484-425-8170		Client Name: TEST CLIENT *THE WAREHOUSE		
Accession T10002950	Collection Date/Time 04/24/2018 1:00 AM	Received Date/Time 04/24/2018 8:34 AM	Ordering provider COMPUTER STAFF LAB			
Specimen Type:		Urine				
Analyte Name	Result	Cut-off	Unit	Notes	Lab	
DRUG SCREEN 2, COC, URINE						
SPECIMEN ID NUMBER	123456				L1	
AMPHETAMINES, EIA	Negative	500	ng/mL		L1	
CANNABINOIDS, EIA	Negative	50	ng/mL		L1	
COCAINE METABOLITE, EIA	Negative	150	ng/mL		L1	
OPIATES LOW, EIA	Negative	300	ng/mL		L1	
PHENCYCLIDINE, EIA	Negative	25	ng/mL		L1	
MDMA, EIA	See Confirmation	500	ng/mL		L1	
6MAM, EIA	Negative	10	ng/mL		L1	
BIOCHEMICAL CHECKS	Pass				L1	
AMPHETAMINE, QN, UR						
AMPHETAMINE (MS)	Negative	250	ng/mL		L1	
METHAMPHETAMINE (MS)	Negative	250	ng/mL		L1	
MDA (MS)	Negative	250	ng/mL		L1	
MDMA (MS)	1000	250	ng/mL	Positive	L1	
Note 1. Screening performed by Enzyme Immunoassay (EIA). 2. Confirmation performed by Liquid Chromatography-Tandem Mass Spectrometry (LC/MS/MS). 3. Negative specimens will be discarded after two weeks from date of the report. 4. Positive samples will be saved frozen for one year unless notified.						
Report electronically signed on 04/24/2018 at 8:40 AM by:  _____ Scientist/Technician, Certifying Scientist						
Name: HNL, DEMO COC MR#: DEMO-27923		End of Report Page: 1 of 1 04/24/2018 08:40 AM				

For more information, please contact your **Laboratory Sales Consultant** or **HNL's Toxicology department** at 877-402-4221.

CPT (Current & Procedural Terminology) is a trademark of the AMA. Codes listed are guidelines and are for informational purposes only. Coding questions should be directed to the third party payor and/or the AMA. OIG guidelines recommend tests ordered should be reasonable and necessary for the patient, given their clinical condition. Physicians who order medically unnecessary tests for which Medicare reimbursement is claimed may be subject to penalties. Individual components of profiles or panels may be ordered individually at an additional charge. Physicians who consider Reflex testing unnecessary may order an initial test without the Reflexed test. Reflex or confirmation tests are performed at an additional charge.